Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
eMedicine - Heart Block, Second Degree : Article by

Quick Find
Authors & Editors
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Multimedia
References

Related Articles
Heart Block, First Degree

Heart Block, Third Degree

Myocardial Infarction




Patient Education
Click here for patient education.



Author: Michael D Levine, MD, Staff Physician, Department of Emergency Medicine, Brigham and Women's Hospital, Massachusetts General Hospital, Harvard Affiliated Emergency Medicine Residency Program

Michael D Levine is a member of the following medical societies: Alpha Omega Alpha, American College of Emergency Physicians, American Medical Association, Emergency Medicine Residents Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Coauthor(s): David FM Brown, MD, Assistant Professor, Department of Medicine, Department of Emergency Medicine, Division of Emergency Medicine, Harvard Medical School; Vice-Chair, Massachusetts General Hospital

Editors: Theodore Gaeta, DO, MPH, Residency Director, Clinical Associate Professor of Emergency Medicine in Medicine, Department of Emergency Medicine, New York Methodist Hospital; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Eddy Lang, MDCM, CCFP (EM), CSPQ, Assistant Professor, Department of Family Medicine, McGill University; Consulting Staff, Department of Emergency Medicine, The Sir Mortimer B Davis-Jewish General Hospital; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; Jonathan Adler, MD, Attending Physician, Department of Emergency Medicine, Massachusetts General Hospital; Division of Emergency Medicine, Harvard Medical School

Author and Editor Disclosure

Synonyms and related keywords: atrioventricular block, second-degree atrioventricular block, AV block, A-V block, second-degree AV block, second-degree A-V block, Mobitz I, Mobitz I heart block, Mobitz I atrioventricular block, Mobitz I AV block, Mobitz I A-V block, Mobitz II, Mobitz II heart block, Mobitz II atrioventricular block, Mobitz II AV block, Mobitz II A-V block, second-degree heart block, atrial impulses, cardiac conduction system, nonconducted atrial impulse

Background

Second-degree heart block, or second-degree atrioventricular (AV) block, refers to a disorder of the cardiac conduction system in which some atrial impulses are not conducted to the ventricles. Electrocardiographically, some P waves are not followed by a QRS complex. Second-degree AV block is composed of 2 types: Mobitz I or Wenckebach block, and Mobitz II.

The Mobitz I second-degree AV block is characterized by a progressive prolongation of the PR interval, which results in a progressive shortening of the R-R interval. Ultimately, the atrial impulse fails to conduct, a QRS complex is not generated, and there is no ventricular contraction. The PR interval is the shortest in the first beat in the cycle, while the R-R interval is the longest in the first beat in the cycle.

The Mobitz II second-degree AV block is characterized by an unexpected nonconducted atrial impulse. Thus, the PR and R-R intervals between conducted beats are constant.

Pathophysiology

Mobitz type I block is caused by conduction delay in the AV node in 72% of patients and by conduction delay in the His-Purkinje system in the remaining 28%. The presence of a narrow QRS complex suggests the site of the delay is more likely to be in the AV node. However, a wide QRS complex may be observed with either AV nodal or infranodal conduction delay.

In Mobitz type II block, the conduction delay occurs infranodally. The QRS complex is likely to be wide, except in patients where the delay is localized to the bundle of His.

Frequency

United States

In the United States, the prevalence of second-degree heart block in young adults is reported to be 0.003%. However, the rate is significantly higher among trained athletes, occurring in 2.4% of athletes undergoing routine ECGs.

Mortality/Morbidity

Mobitz type I second-degree AV block is localized to the AV node, and thus is not associated with any increased risk of morbidity or death, in the absence of organic heart disease. In addition, when the block is localized to the AV node, no risk of progression to a type II second-degree block or complete heart block exists. However, when a Mobitz type I block occurs during an acute myocardial infarction, mortality is increased. Mobitz type II blocks do carry a risk of progressing to complete heart block, and thus are associated with an increased risk of mortality. Mobitz I blocks localized to the His-Purkinje system are associated with the same risks as type II blocks.



History

  • Mobitz I (Wenckebach) block
    • Most patients are asymptomatic.

    • Patients may experience light-headedness, dizziness, or syncope, but these symptoms are uncommon.

    • Patients may have chest pain if the heart block is related to myocarditis or ischemia.

    • Patients may have a history of structural heart disease.

  • Mobitz II block
    • Unlike Mobitz I block, patients with type II block are more likely to experience light-headedness, dizziness, or syncope, although they may be asymptomatic as well.

    • Patients may have chest pain if the heart block is related to myocarditis or ischemia.

Physical

  • Patients often have a regularly irregular heartbeat.
  • Bradycardia may be present.
  • Symptomatic patients may have signs of hypoperfusion, including hypotension.

Causes

  • Mobitz I block can occur in individuals with high vagal tone, such as athletes or young children.
  • Mobitz I block can occur in infants and young children with structural heart disease (eg, tetralogy of Fallot) and in individuals of any age following valvular surgery (especially mitral valve).
  • Other causes of type I block include myocardial infarction (especially inferior wall), and drug induced (including beta-blockers, calcium channel blockers, amiodarone, digoxin, and possibly pentamidine).
  • Mobitz II block most commonly is caused by an acute myocardial infarction (anterior or inferior). Drug-induced etiologies can also occur.



Heart Block, First Degree
Heart Block, Third Degree
Myocardial Infarction

Other Problems to be Considered

Heart block, congenital



Lab Studies

  • Serum electrolytes, calcium, and magnesium levels should be checked.
  • A digoxin level should be obtained for patients on digoxin.
  • Cardiac enzymes tests are indicated for any patient with suspected myocardial ischemia.
  • Myocarditis-related laboratory studies (eg, Lyme titers, HIV serologies, enterovirus polymerase chain reaction [PCR], adenovirus PCR, Chagas titers), if clinically relevant.

Imaging Studies

  • Routine imaging studies are not required. However, if myocarditis is a concern, an ECHO may be indicated. If myocardial ischemia is a concern, a chest radiograph may be indicated.

Other Tests

  • Follow-up ECGs and cardiac monitoring are appropriate.



Prehospital Care

  • Second-degree heart block in the asymptomatic patient does not require any specific therapy in the prehospital setting.
  • If the patient is symptomatic, standard advanced cardiac life support (ACLS) guidelines for bradycardia, including the use of atropine and transcutaneous pacing, is indicated.

Emergency Department Care

  • Mobitz I (Wenckebach) block
    • No specific therapy is required in the ED, unless the patient is symptomatic.

    • Patients with suspected myocardial ischemia should be treated with an appropriate anti-ischemic regimen.

    • AV nodal blocking agents (including beta-blockade) should be avoided.

    • Symptomatic patients should be treated with atropine and transcutaneous pacing. However, atropine should be administered with caution in patients with suspected myocardial ischemia, as ventricular dysrhythmias can occur in this situation.

  • Mobitz II block
    • As with type I block, AV nodal agents should be avoided, and an anti-ischemic regimen should be instituted if ischemia is suspected.

    • Transcutaneous pacing pads should be applied to all patients, including asymptomatic patients, as patients with Mobitz II second-degree AV block have a propensity to progress to complete heart block. The transcutaneous pacemaker should be tested to ensure capture. If capture is not able to be achieved, then insertion of a transvenous pacemaker is indicated, even in asymptomatic patients.

    • Urgent cardiology consult is indicated for patients who have symptomatic type II block and for those asymptomatic patients who are unable to achieve capture with transcutaneous pacing.

    • Some institutions recommend insertion of a transvenous pacemaker for all new Mobitz type II blocks, although this practice varies greatly from institution to institution.

    • Patients who are hemodynamically unstable for whom an emergent cardiology consult is not available should undergo placement of a temporary transvenous pacing wire in the ED. A chest radiograph is required to confirm position of the wire and to exclude complications, including hemothorax or pneumothorax.

Consultations

  • For symptomatic patients with Mobitz I block, a cardiology consultation is indicated. Asymptomatic patients with a Mobitz I block can be referred to a cardiologist on an outpatient basis.
  • For any patient with a new Mobitz II block, cardiology consultation is indicated, regardless of symptoms.



The goal of therapy is to improve conduction through the AV node by reducing vagal tone via atropine-induced receptor blockade. However, this goal will only be effective if the level of the blockade is at the site of the AV node. Patients with infranodal second-degree heart block are unlikely to benefit from atropine. In addition, in patients who have deinervated hearts (eg, patients who have a cardiac transplant), atropine is also not likely to be effective.

Drug Category: Anticholinergic

Drug therapy in second-degree heart block is aimed at vagolysis; atropine is the only currently recommended agent.

Drug NameAtropine (Atropair, Atropine-Care, Isopto)
DescriptionEnhances sinus node automaticity. In addition, blocks the effects of acetylcholine at the AV node, thereby decreasing the refractory time and speeding conduction through the AV node. Insufficient doses can cause paradoxical effects, further slowing the heart rate
Adult Dose0.5 mg rapid IV push; for patients in PEA arrest, administer 1 mg; 0.04 mg/kg IV maximum; can also be administered via endotracheal tube, although absorption is less predictable compared with IV administration; if administered via endotracheal tube, dose should be increased 2-3 fold
Pediatric Dose0.02 mg/kg IV push, with minimum of 0.1 mg; any single dose should not exceed 0.5 mg/dose IV in children or 1 mg/dose in adolescents; maximal total IV dose is 0.04 mg/kg; can be administered via endotracheal tube, although absorption is less predictable compared with IV administration; if administered via endotracheal tube, dose should be increased 2-3 fold
ContraindicationsDocumented hypersensitivity to belladonna alkaloids or related products; concomitant acute myocardial ischemia/infarction, thyrotoxicosis, narrow-angle glaucoma, or tachycardia; Down syndrome or brain damage in children (may show hyperreactive response to topical atropine); coronary artery disease; congestive heart failure; hypertension
InteractionsCoadministration with other anticholinergics have additive effects; pharmacologic effects of atenolol and digoxin may increase with atropine; antipsychotic effects of phenothiazines may decrease with this medication; tricyclic antidepressants with anticholinergic activity may increase effects of atropine
PregnancyC - Safety for use during pregnancy has not been established.
PrecautionsCaution in Down syndrome and/or children with brain damage to prevent hyperreactive response; caution also in coronary heart disease, tachycardia, congestive heart failure, cardiac arrhythmias, hypertension, peritonitis, ulcerative colitis, hepatic disease, and hiatal hernia with reflux esophagitis; in prostatic hypertrophy, prostatism can have dysuria and may require catheterization



Further Inpatient Care

  • Mobitz I (Wenckebach) block
    • Admit the patient with symptoms or with concomitant acute myocardial ischemia/infarction.

    • Admission should be to a unit with telemetry monitoring, which has transcutaneous pacing capabilities.

  • Mobitz II block
    • Admit all patients to a unit with monitored beds, where transcutaneous and transvenous pacing capabilities are available.

    • The admitting cardiologist should determine whether permanent pacemaker implantation is indicated.

Further Outpatient Care

  • Patients who are discharged from the ED with Wenckebach block should have prompt follow-up arranged with a cardiologist.

Prognosis

  • Wenckebach block carries a good prognosis with appropriate follow-up and treatment.
  • Mobitz II block is more dangerous, as it progresses more frequently to complete heart block with hemodynamic instability. In addition, it is associated with myocardial infarction, and all its attendant risks.



Media file 1:  An electrocardiogram of a patient with Mobitz I (Wenckebach) second-degree AV block.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  ECG

Media file 2:  An electrocardiogram of a patient with Mobitz II second-degree AV block.
Click to see larger pictureClick to see detailView Full Size Image
Media type:  ECG



  • American Heart Association. Guidelines for cardiopulmonary resuscitation and emergency cardiac care. Emergency Cardiac Care Committee and Subcommittees, American Heart Association. Part III. Adult advanced cardiac life support. JAMA. Oct 28 1992;268(16):2199-241. [Medline].
  • Antoniou T, Gough KA. Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: case report and review of the literature. Pharmacotherapy. Jun 2005;25(6):899-903. [Medline].
  • Ariyarajah V, Asad N, Tandar A, Spodick DH. Interatrial block: pandemic prevalence, significance, and diagnosis. Chest. Aug 2005;128(2):970-5. [Medline].
  • Meimoun P, Zeghdi R, D'Attelis N, Berrebi A, Braunberger E, Deloche A. Frequency, predictors, and consequences of atrioventricular block after mitral valve repair. Am J Cardiol. May 1 2002;89(9):1062-6. [Medline].
  • Stein R, Medeiros CM, Rosito GA, Zimerman LI, Ribeiro JP. Intrinsic sinus and atrioventricular node electrophysiologic adaptations in endurance athletes. J Am Coll Cardiol. Mar 20 2002;39(6):1033-8. [Medline].
  • Strasberg B, Amat-Y-Leon F, Dhingra RC, Palileo E, Swiryn S, Bauernfeind R. Natural history of chronic second-degree atrioventricular nodal block. Circulation. May 1981;63(5):1043-9. [Medline].
  • Syverud S. Cardiac pacing. Emerg Med Clin North Am. May 1988;6(2):197-215. [Medline].
  • Zehender M, Meinertz T, Keul J, Just H. ECG variants and cardiac arrhythmias in athletes: clinical relevance and prognostic importance. Am Heart J. Jun 1990;119(6):1378-91. [Medline].

Heart Block, Second Degree excerpt

Article Last Updated: Sep 5, 2006